Cargando…

The role of substantia nigra sonography in the differentiation of Parkinson’s disease and multiple system atrophy

BACKGROUND: The differential diagnosis of Parkinson’s disease (PD) and multiple system atrophy (MSA) remains a challenge, especially in the early stage. Here, we assessed the value of transcranial sonography (TCS) to discriminate non-tremor dominant (non-TD) PD from MSA with predominant parkinsonism...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Hai-Yan, Huang, Pei, Sun, Qian, Du, Juan-Juan, Cui, Shi-Shuang, Hu, Yun-Yun, Zhan, Wei-Wei, Wang, Ying, Xiao, Qin, Liu, Jun, Tan, Yu-Yan, Chen, Sheng-Di
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055347/
https://www.ncbi.nlm.nih.gov/pubmed/30062008
http://dx.doi.org/10.1186/s40035-018-0121-0
_version_ 1783341154296659968
author Zhou, Hai-Yan
Huang, Pei
Sun, Qian
Du, Juan-Juan
Cui, Shi-Shuang
Hu, Yun-Yun
Zhan, Wei-Wei
Wang, Ying
Xiao, Qin
Liu, Jun
Tan, Yu-Yan
Chen, Sheng-Di
author_facet Zhou, Hai-Yan
Huang, Pei
Sun, Qian
Du, Juan-Juan
Cui, Shi-Shuang
Hu, Yun-Yun
Zhan, Wei-Wei
Wang, Ying
Xiao, Qin
Liu, Jun
Tan, Yu-Yan
Chen, Sheng-Di
author_sort Zhou, Hai-Yan
collection PubMed
description BACKGROUND: The differential diagnosis of Parkinson’s disease (PD) and multiple system atrophy (MSA) remains a challenge, especially in the early stage. Here, we assessed the value of transcranial sonography (TCS) to discriminate non-tremor dominant (non-TD) PD from MSA with predominant parkinsonism (MSA-P). METHODS: Eighty-six MSA-P patients and 147 age and gender-matched non-TD PD patients who had appropriate temporal acoustic bone windows were included in this study. All the patients were followed up for at least 2 years to confirm the initial diagnosis. Patients with at least one substantia nigra (SN) echogenic size ≥18 mm(2) were classified as hyperechogenic, those with at least one SN echogenic size ≥25 mm(2) was defined as markedly hyperechogenic. RESULTS: The frequency of SN hyperechogenicity in non-TD PD patients was significantly higher than that in MSA-P patients (74.1% vs. 38.4%, p <  0.001). SN hyperechogenicity discriminated non-TD PD from MSA-P with sensitivity of 74.1%, specificity of 61.6%, and positive predictive value of 76.8%. If marked SN hyperechogenicity was used as the cutoff value (≥ 25 mm(2)), the sensitivity decreased to 46.3%, but the specificity and positive predictive value increased to 80.2 and 80.0%. Additionally, in those patients with SN hyperechogenicity, positive correlation between SN hyperechogenicity area and disease duration was found in non-TD PD rather than in MSA-P patients. In this context, among early-stage patients with disease duration ≤3 years, the sensitivity, specificity and positive predictive value of SN hyperechogenicity further declined to 69.8%, 52.2%, and 66.7%, respectively. CONCLUSIONS: TCS could help discriminate non-TD PD from MSA-P in a certain extent, but the limitation was also obvious with relatively low specificity, especially in the early stage.
format Online
Article
Text
id pubmed-6055347
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-60553472018-07-30 The role of substantia nigra sonography in the differentiation of Parkinson’s disease and multiple system atrophy Zhou, Hai-Yan Huang, Pei Sun, Qian Du, Juan-Juan Cui, Shi-Shuang Hu, Yun-Yun Zhan, Wei-Wei Wang, Ying Xiao, Qin Liu, Jun Tan, Yu-Yan Chen, Sheng-Di Transl Neurodegener Research BACKGROUND: The differential diagnosis of Parkinson’s disease (PD) and multiple system atrophy (MSA) remains a challenge, especially in the early stage. Here, we assessed the value of transcranial sonography (TCS) to discriminate non-tremor dominant (non-TD) PD from MSA with predominant parkinsonism (MSA-P). METHODS: Eighty-six MSA-P patients and 147 age and gender-matched non-TD PD patients who had appropriate temporal acoustic bone windows were included in this study. All the patients were followed up for at least 2 years to confirm the initial diagnosis. Patients with at least one substantia nigra (SN) echogenic size ≥18 mm(2) were classified as hyperechogenic, those with at least one SN echogenic size ≥25 mm(2) was defined as markedly hyperechogenic. RESULTS: The frequency of SN hyperechogenicity in non-TD PD patients was significantly higher than that in MSA-P patients (74.1% vs. 38.4%, p <  0.001). SN hyperechogenicity discriminated non-TD PD from MSA-P with sensitivity of 74.1%, specificity of 61.6%, and positive predictive value of 76.8%. If marked SN hyperechogenicity was used as the cutoff value (≥ 25 mm(2)), the sensitivity decreased to 46.3%, but the specificity and positive predictive value increased to 80.2 and 80.0%. Additionally, in those patients with SN hyperechogenicity, positive correlation between SN hyperechogenicity area and disease duration was found in non-TD PD rather than in MSA-P patients. In this context, among early-stage patients with disease duration ≤3 years, the sensitivity, specificity and positive predictive value of SN hyperechogenicity further declined to 69.8%, 52.2%, and 66.7%, respectively. CONCLUSIONS: TCS could help discriminate non-TD PD from MSA-P in a certain extent, but the limitation was also obvious with relatively low specificity, especially in the early stage. BioMed Central 2018-07-23 /pmc/articles/PMC6055347/ /pubmed/30062008 http://dx.doi.org/10.1186/s40035-018-0121-0 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Zhou, Hai-Yan
Huang, Pei
Sun, Qian
Du, Juan-Juan
Cui, Shi-Shuang
Hu, Yun-Yun
Zhan, Wei-Wei
Wang, Ying
Xiao, Qin
Liu, Jun
Tan, Yu-Yan
Chen, Sheng-Di
The role of substantia nigra sonography in the differentiation of Parkinson’s disease and multiple system atrophy
title The role of substantia nigra sonography in the differentiation of Parkinson’s disease and multiple system atrophy
title_full The role of substantia nigra sonography in the differentiation of Parkinson’s disease and multiple system atrophy
title_fullStr The role of substantia nigra sonography in the differentiation of Parkinson’s disease and multiple system atrophy
title_full_unstemmed The role of substantia nigra sonography in the differentiation of Parkinson’s disease and multiple system atrophy
title_short The role of substantia nigra sonography in the differentiation of Parkinson’s disease and multiple system atrophy
title_sort role of substantia nigra sonography in the differentiation of parkinson’s disease and multiple system atrophy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055347/
https://www.ncbi.nlm.nih.gov/pubmed/30062008
http://dx.doi.org/10.1186/s40035-018-0121-0
work_keys_str_mv AT zhouhaiyan theroleofsubstantianigrasonographyinthedifferentiationofparkinsonsdiseaseandmultiplesystematrophy
AT huangpei theroleofsubstantianigrasonographyinthedifferentiationofparkinsonsdiseaseandmultiplesystematrophy
AT sunqian theroleofsubstantianigrasonographyinthedifferentiationofparkinsonsdiseaseandmultiplesystematrophy
AT dujuanjuan theroleofsubstantianigrasonographyinthedifferentiationofparkinsonsdiseaseandmultiplesystematrophy
AT cuishishuang theroleofsubstantianigrasonographyinthedifferentiationofparkinsonsdiseaseandmultiplesystematrophy
AT huyunyun theroleofsubstantianigrasonographyinthedifferentiationofparkinsonsdiseaseandmultiplesystematrophy
AT zhanweiwei theroleofsubstantianigrasonographyinthedifferentiationofparkinsonsdiseaseandmultiplesystematrophy
AT wangying theroleofsubstantianigrasonographyinthedifferentiationofparkinsonsdiseaseandmultiplesystematrophy
AT xiaoqin theroleofsubstantianigrasonographyinthedifferentiationofparkinsonsdiseaseandmultiplesystematrophy
AT liujun theroleofsubstantianigrasonographyinthedifferentiationofparkinsonsdiseaseandmultiplesystematrophy
AT tanyuyan theroleofsubstantianigrasonographyinthedifferentiationofparkinsonsdiseaseandmultiplesystematrophy
AT chenshengdi theroleofsubstantianigrasonographyinthedifferentiationofparkinsonsdiseaseandmultiplesystematrophy
AT zhouhaiyan roleofsubstantianigrasonographyinthedifferentiationofparkinsonsdiseaseandmultiplesystematrophy
AT huangpei roleofsubstantianigrasonographyinthedifferentiationofparkinsonsdiseaseandmultiplesystematrophy
AT sunqian roleofsubstantianigrasonographyinthedifferentiationofparkinsonsdiseaseandmultiplesystematrophy
AT dujuanjuan roleofsubstantianigrasonographyinthedifferentiationofparkinsonsdiseaseandmultiplesystematrophy
AT cuishishuang roleofsubstantianigrasonographyinthedifferentiationofparkinsonsdiseaseandmultiplesystematrophy
AT huyunyun roleofsubstantianigrasonographyinthedifferentiationofparkinsonsdiseaseandmultiplesystematrophy
AT zhanweiwei roleofsubstantianigrasonographyinthedifferentiationofparkinsonsdiseaseandmultiplesystematrophy
AT wangying roleofsubstantianigrasonographyinthedifferentiationofparkinsonsdiseaseandmultiplesystematrophy
AT xiaoqin roleofsubstantianigrasonographyinthedifferentiationofparkinsonsdiseaseandmultiplesystematrophy
AT liujun roleofsubstantianigrasonographyinthedifferentiationofparkinsonsdiseaseandmultiplesystematrophy
AT tanyuyan roleofsubstantianigrasonographyinthedifferentiationofparkinsonsdiseaseandmultiplesystematrophy
AT chenshengdi roleofsubstantianigrasonographyinthedifferentiationofparkinsonsdiseaseandmultiplesystematrophy